Fmr LLC boosted its holdings in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 26.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,039,109 shares of the company’s stock after acquiring an additional 2,095,706 shares during the period. Fmr LLC’s holdings in Amneal Pharmaceuticals were worth $222,767,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Fosun International Ltd acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $333,013,000. BlackRock Inc. increased its stake in shares of Amneal Pharmaceuticals by 2.1% in the third quarter. BlackRock Inc. now owns 5,931,927 shares of the company’s stock valued at $131,629,000 after purchasing an additional 123,844 shares during the period. TPG Group Holdings SBS Advisors Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $67,438,000. Frontier Capital Management Co. LLC increased its stake in shares of Amneal Pharmaceuticals by 37.1% in the third quarter. Frontier Capital Management Co. LLC now owns 2,876,367 shares of the company’s stock valued at $63,827,000 after purchasing an additional 777,764 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Amneal Pharmaceuticals by 278.9% in the third quarter. Janus Henderson Group PLC now owns 2,723,178 shares of the company’s stock valued at $60,427,000 after purchasing an additional 2,004,464 shares during the period. 35.93% of the stock is currently owned by hedge funds and other institutional investors.
NYSE AMRX opened at $17.67 on Thursday. Amneal Pharmaceuticals Inc has a 12 month low of $13.47 and a 12 month high of $24.48. The company has a current ratio of 1.91, a quick ratio of 1.26 and a debt-to-equity ratio of 2.92. The company has a market cap of $5.29 billion, a P/E ratio of 28.05, a P/E/G ratio of 0.88 and a beta of 1.48.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.01. Amneal Pharmaceuticals had a negative net margin of 36.54% and a positive return on equity of 4.98%. The business had revenue of $476.50 million for the quarter, compared to analyst estimates of $486.01 million. The company’s quarterly revenue was up 87.1% compared to the same quarter last year. Sell-side analysts predict that Amneal Pharmaceuticals Inc will post 0.92 EPS for the current fiscal year.
Several equities research analysts have commented on AMRX shares. Royal Bank of Canada upgraded shares of Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research note on Monday, August 13th. ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 27th. Canaccord Genuity restated a “hold” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Tuesday, September 4th. SunTrust Banks lowered shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price objective on the stock. in a research note on Tuesday, October 16th. Finally, B. Riley raised their price objective on shares of Amneal Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, August 22nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $22.75.
TRADEMARK VIOLATION WARNING: “Fmr LLC Acquires 2,095,706 Shares of Amneal Pharmaceuticals Inc (AMRX)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/06/fmr-llc-acquires-2095706-shares-of-amneal-pharmaceuticals-inc-amrx.html.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Dollar Cost Averaging
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.